Control of hypoxia-inducible gene expression with oligooxopiperazine nonpeptidic helix mimetics
US9783526B2 · kind B2 · utility
2Cited by
3References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 8, 2016 |
| Grant date | Oct 10, 2017 |
| Priority date | — |
| Expiry date | Feb 8, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N15/63
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to oligooxopiperazines that mimic helix αB of the C-terminal transactivation domain of HIF-1α. Also disclosed are pharmaceutical compositions containing these oligooxopiperazines and methods of using these oligooxopiperazines (e.g., to reduce gene transcription, treat or prevent disorders mediated by interaction of HIF-1α with CREB-binding protein and/or p300, reduce or prevent angiogenesis in a tissue, induce apoptosis, and decrease cell survival and/or proliferation).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.